Nuvilex, Inc. Moves Closer to “Bio-Artificial Pancreas” Diabetes Treatment With License for Insulin-Producing Cells

NEW YORK, NY–(Marketwired – October 21, 2014) – Nuvilex, Inc. (NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology. It started in November 2013 when the company acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development…